Shareholders Approve Substantial Increase in Equity Incentive Plan Shares
ICU sits 48% above its 52-week low of $2.07 on light trading volume (0.3× avg).
Summary
SeaStar Medical shareholders approved a significant increase in the shares available for its equity incentive plan, authorizing an additional 689,500 shares for future compensation awards.
Key Events · Financing and Capital Events · ICU
-
Equity Incentive Plan Expansion Approved
Shareholders approved an amendment and restatement of the 2022 Omnibus Incentive Plan, increasing the number of shares authorized for equity awards.
-
Significant Share Increase
The number of shares available for issuance under the plan increased by 689,500, from 207,046 to 896,546. These figures are already adjusted for the 1-for-10 reverse stock split on January 5, 2026.
-
Routine Governance Matters
Shareholders also re-elected John Neuman as a Class I director and ratified WithumSmith+Brown, PC as the independent registered public accounting firm for 2026.
Analysis · ICU · Industrial Applications And Services
Shareholders approved a substantial increase in the shares reserved for the company's equity incentive plan. This authorization of an additional 689,500 shares, representing a significant potential increase in outstanding shares, allows SeaStar Medical to use equity for compensation, which is critical for attracting and retaining talent, especially given its 'going concern' warning. However, it also introduces considerable potential dilution for existing shareholders.
At the time of this filing, ICU was trading at $3.06 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $12.2M. The 52-week trading range was $2.07 to $12.50. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.